Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24

Pti: Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24

Related Keywords

South Africa ,India ,United States ,Mumbai ,Maharashtra ,China ,America ,Glenmark Pharma ,Glenn Saldanha ,Glenmark Europe ,Linkedin Glenmark Pharmaceuticals ,Glenmark Pharmaceuticals Limited ,Instagram ,Biosimilars Companies ,Indian Pharmaceuticals ,Glenmark Life Sciences ,Glenmark Life Sciences Ltd ,Glenmark Pharmaceuticals ,Prnewswire Glenmark Pharmaceuticals Ltd ,Glenmark Pharmaceuticals Ltd ,Glenmark Life Sciences Limited ,Source Name ,India Business ,North America Business ,Continuing Operations ,Managing Director ,Nirma Limited ,Pharmaceuticals Limited ,Pharmaceutical Sales ,Biosimilars Companies Ranked ,Great Place To Work ,Green House Gas ,Science Based Target ,Glenmark ,Pharma ,Reports ,Consolidated ,Revenue ,Growth ,Of ,6 ,3 , ,Hand ,Adjusted ,Ebitda , 8 ,Wyoy ,For ,Q2 ,Fy ,2023 ,24 ,